Mesa Laboratories Inc (MLAB)
117.59
-0.57
(-0.48%)
USD |
NASDAQ |
Nov 05, 10:23
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 636.07M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 27.54% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.838 |
| Price to Book Value | 4.220 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.16 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.408 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 74.40% |
Profile
| Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products. |
| URL | https://www.mesalabs.com |
| Investor Relations URL | https://investors.mesalabs.com |
| HQ State/Province | Colorado |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 06, 2024 (est.) |
| Last Earnings Release | Aug. 05, 2024 |
| Next Ex-Dividend Date | Nov. 29, 2024 |
| Last Ex-Dividend Date | Aug. 30, 2024 |
Ratings
Profile
| Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products. |
| URL | https://www.mesalabs.com |
| Investor Relations URL | https://investors.mesalabs.com |
| HQ State/Province | Colorado |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 06, 2024 (est.) |
| Last Earnings Release | Aug. 05, 2024 |
| Next Ex-Dividend Date | Nov. 29, 2024 |
| Last Ex-Dividend Date | Aug. 30, 2024 |